“The linking of specific cancer genetic alterations to molecular ...€¦ · “The linking of...

“The linking of specific cancer genetic alterations to molecular targeted therapies is driving a new era of personalised medicine”

Oncologica addresses this new era of precision medicine by exploiting state of the art molecular profiling enabling a patient’s tumour to be matched directly with the most appropriate molecular targeted therapy.

Oncologica’s semiconductor profiling technology reduces the number of tests required for comprehensive tumour analysis, delivers faster results and at a much lower cost.

Our scientists and clinicians utilise state-of-the-art next generation semiconductor sequencing technology (NGS) to rapidly detect actionable mutations in patients’ tumour samples to precisely match these alterations with new generation targeted therapies.

The Oncofocus Assay, a targeted sequencing platform, is designed to detect actionable mutations in cancer genes targeted by on-market oncology drugs or treatments in clinical trials. Intelligent design is driven by Oncologica’s bioinformatics platforms linked to the world’s largest curated compendium of cancer genomic information, including content aligned to approved therapies, current practice guidelines and open clinical trials.

Our targeted next generation sequencing assay enables simultaneous detection of thousands of genetic variants across 52 genes relevant to solid tumours. Targeted actionable hotspots include SNVs, indels, CNVs and gene fusions.

Analysis of the output from the Oncofocus assay is performed using Oncofocus Reporter, an analytical system used to identify and prioritise potential treatment strategies. This analytical platform enables Oncofocus detected variants to be linked to over 270 targeted therapies

NGS

C

G

T

A

Oncologica carries out DNA sequencing of patients’ tumour samples using semiconductor chip technology directly translating chemically encoded information (A, C, G, T) into digital information.

Semiconductor sequencing has major advantages over other sequencing technologies because it can be used to sequence low DNA/RNA input FFPE biopsy samples with high throughput and at a reduced cost.

• Nucleotides flow sequentially over an Ion semiconductor chip

• One sensor per well per sequencing reaction

• Direct detection of natural DNA extension

• Millions of sequencing reactions per chip

• Fast cycle time, real time detection

NEXT GENERATION SEQUENCING (NGS)TECHNOLOGY

Ion semiconductor chip

dNTP

H+

sensing layersensor plate

silicon substratebulk drain source

DNA Ions Sequence

To columnreceiver

Rothberg J.M. et al Nature doi:10/1038/nature10242

THE FIRST LABORATORY IN EUROPE TO OFFER ONCOFOCUS The world’s most comprehensive precision oncology test

4 5

Delivering New Generation MolecularProfiling for cancer targeted therapies

to optimize treatment efficacyComprehensive analysis of major cancer driver genes in one single workflow dramatically reducing the cost of molecular profiling and accelerating reporting times

Reduced number of tests that cancer patients require

NGS semiconductor platform uses low DNA/RNA input (10ng) from FFPE samples enabling detection of actionable variants in fine needle biopsies and core needle aspirates

Generates a comprehensive picture of actionable mutations providing the clinician with a detailed molecular blueprint for optimal therapy choices and improved patient outcomes

Prevent the unwarranted prescribing of expensive targeted therapies to patients unlikely to benefit from such treatments

Identification of specific mutations known to be associated with response or resistance to targeted therapies

Identification of new driver mutations following relapse allowing a switch to additional more appropriate targeted therapies

Identification of driver mutations and linked therapies in rare tumour types for which treatment protocols are limited

Molecular profiling conducted on routine diagnostic histological samples (formalin fixed paraffin embedded specimens) and liquid biopsies including circulating tumour DNA and circulating tumour cells (ctDNA and CTCs)

6 7

TARGETED NGS FOR ALL SOLID TUMOUR TYPES

TARGETED TREATMENTS

ALK FUSION

BRAF MUTATION

COBIMETINIB + RG-7446

CABOZANTINIB

CETUXIMAB

PANITUMUMAB

VORINOSTAT

DASATINIB

AFATINIB

CERITINIB + CHEMOTHERAPY

NERATINIB

DABRAFENIB

EVEROLIMUS

KIT FUSION

EGFR MUTATION

ERBB2 AMPLIFICATION

PDGFRA AMPLIFICATION

CDKN2A MUTATION

SMO MUTATION

NTRK2 FUSION

RET MUTATION

KIT MUTATION

FGFR4 MUTATIONERBB2 AMPLIFICATION

PIK3CA AMPLIFICATION

CLR-457

IMATINIB MESYLATE

Bladder

Breast

Colorectal

Endometrial

Oesophagus

Gastric

Mesothelioma Osteosarcoma

Ovarian Pancreatic

GIST

Glioblastoma

Head and Neck

Kidney

Liver

Testicular

Thyroid

Prostate

Skin

Small Cell Lung Cancer

Soft Tissue SarcomaNon Small Cell Lung Cancer

MELANOMA

AFATINIB

TRASTUZUMAB

VEMURAFENIB

CRIZOTINIB

NTRK3 MUTATION

ROS1 FUSION

FGFR3 FUSION

ERBB2 AMPLIFICATION

EGFR MUTATION

BRAF MUTATION

PDGFRA MUTATION

NTRK2 MUTATION

The fully integrated Oncofocus Assay and linked Oncofocus Reporter Database provides unparalleled information regarding an individual’s tumour that can be exploited to optimise treatment selection using the new generation of molecular targeted agents.

TUMOUR TYPE GENETIC VARIANTS

35 genes and hundreds of variants tested in this tumour type

TARGETED THERAPIES

Over 110 potential treatments in this tumour type

8 9


FGFR2 AMPLIFICATION

AXL FUSION

MET FUSION

TSC2 MUTATION

SMO MUTATION

AXL FUSION

Bladder

Breast

Colorectal

Endometrial

Oesophagus

Gastric


Ovarian Pancreatic

GIST

Glioblastoma

Head and Neck

Kidney

Liver

Testicular

Thyroid

Prostate

Skin


Soft Tissue SarcomaNon Small Cell Lung Cancer

EGFR FUSION

AKL FUSION

PDGFRA MUTATION

CDK4 MUTATION

HRAS MUTATION

CRIZOTINIB + DASATINIB

IPILIMUMAB

VEMURAFENIB

IMATINIB MESYLATE

VORINOSTAT

CABOZANTINIB

CLR-457

JNJ-42756493

CETUXIMAB

DABRAFENIB

ERLOTINIB

NERATINIB

ABL1 ABERRATION

PTCH1 MUTATION

RET MUTATION

BRAF MUTATIONERBB2 AMPLIFICATION

EGFR MUTATION

AFATINIB

DABRAFENIB + TRAMETINIB

MGCD-265

JNJ-42756493

CERITINIB

RIBOCICLIB

NTRK3 MUTATION

CDK4 MUTATION

EGFR AMPLIFICATIONFGFR2 FUSION

PROSTATE



TARGETED THERAPIES


NTRK2 FUSION

MAP2K1 MUTATION

ALK FUSION

TARGETED TREATMENTSThe fully integrated Oncofocus Assay and linked Oncofocus Reporter Database provides unparalleled information regarding an individual’s tumour that can be exploited to optimise treatment selection using the new generation of molecular targeted agents.

10 11


ERBB2 MUTATION

MET AMPLIFICATION

MET FUSIONTSC2 MUTATION

KRAS MUTATION

Bladder

Breast

Colorectal

Endometrial

Oesophagus

Gastric


Ovarian Pancreatic

GIST

Glioblastoma

Head and Neck

Kidney

Liver

Testicular

Thyroid

Prostate

Skin


Soft Tissue Sarcoma

RET FUSION

MET AMPLIFICATION

KIT MUTATION

BRAF MUTATION

PDGFRA MUTATION

LUNG

HRAS MUTATION

NIVOLUMABDASATINIB

IMATINIB MESYLATE

TRASTUZUMAB + CAPECITABINE

GEFITINIBVEMURAFENIB

CLR-457

AZD-9291

AFATINIB

DABRAFENIB

PALBOCICLIB

EGFR MUTATION

PTCH1 MUTATION

RET MUTATION

ALK FUSION

KRAS G12 MUTATION CETUXIMAB*

CRIZOTINIB

CRIZOTINIB

ERLOTINIB

CABOZANTINIB

DASATINIB

ERBB2 AMPLIFICATION

EGFR MUTATION

ALK FUSION

PDGFRA MUTATION

CDK4 MUTATION

EGFR MUTATION



TARGETED THERAPIES


*contraindicate

TARGETED TREATMENTSThe fully integrated Oncofocus Assay and linked Oncofocus Reporter Database provides unparalleled information regarding an individual’s tumour that can be exploited to optimise treatment selection using the new generation of molecular targeted agents.

12 13

Life Technologies Clinical Services Lab 910 Riverside Parkway, Suite 60 | West Sacramento, CA 95605

Ph: (888) 734-8588 | Fax: (855) 896-0909 [email protected] | lifelabdx.com

Oncomine Cancer Panel Patient Test Report

SUBJECT INFORMATION

SITE INFORMATION

Pre-Screening Subject No.: ________________________ Investigator Name: __________________________________ Subject Initials: ___________ (first/middle/last)

Date of Birth: _________ (dd/mmm/yyyy)

Site ID: _______________

Date of Shipment: __________ (dd/mmm/yyyy)

Gender: ☐ M ☐ F

Phone: ________________

Fax: _____________________

SPECIMEN INFORMATION Accession No.: __________________

Date Specimen Received: ________________

Date Reported: _______________

TEST RESULTS

In this cancer type In other cancer type In this cancer type and other

cancer types Contraindicated No evidence available

Mutations

Gene Amino Acid

Change Geneotype Classification

Current FDA Information

NCCN Guideline

Number of therapies with clinical trials in this

therapies

KRAS p.Ala146Thr c.436G>A Gain of Function 2 15

KIT p.Met541Leu c.1612A>C Gain of Function 1 1

MET p.Asn375Ser c.1124A>G Gain of Function 3

TP53 p.Arg234Cys c.700C>T Loss of Function 1

TP53 p.Pro33Arg c.98C>G Loss of Function 1

Copy Number Variations

Gene Type Classification Current FDA Information

NCCN Guideline

Number of therapies with clinical trials in this therapies

PTEN Deletion Loss of Function 5

There is no current FDA information, NCCN guidelines, or open clinical trials for the following detected copy number variations: RPS6KB1 Amplification, FLT3 Amplification, ACVRL1 Amplification, PTCH1 Deletion, CDKN2A Deletion, MYC Amplification, TERT Amplification, TET2 Deletion, VHL Deletion. Other mutations, copy number variations, or fusions of that were detected but not classified by the Oncomine Knowledgebase as a genetic driver of cancer are not listed in the results section of this report. All other genes listed in the Test Description that do not appear in the results section either did not have a detected variant or the variant is not classified as a genetic driver for cancer.

Laboratory director: John E. Glassco, MD, FCAP CLIA number: 05D1067109

Life Technologies Clinical Services Lab tests are intended for clinical use. They were developed and their performance characteristics determined by the Life Technologies Clinical Services Lab, which is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) to perform high complexity testing. The tests have not been cleared or approved by the United States Food and Drug Administration; however, such clearance or approval is not currently required. ©2014 Life Technologies Corporation. All rights reserved. The trademarks mentioned herein are the property of Life Technologies Corporation and/or its affiliate(s).

ONCOFOCUS PATIENT TEST REPORT

TEST RESULTS SUMMARY

Publishedtherapiessummary

Inthiscancer

type

Inothercancer

type

Inthiscancertypeand

othercancertypes

Contraindicated Noevidence

available

(IV),(III),(II/III),(II),(I/II),(I)

Clinicaltrialphase

PublishedtherapyCurrentFDAinformation

NCCNGuidelines

Openclinicaltrialsforthiscancertype*

cetuximab

panitumumab

panitumumab+chemotherapy (II)

regorafenib+FOLFIRI (II)

sorafenib+cetuximab (II)

binimetinib+panitumumab (I/II)

BVD-523 (I/II)

navitoclax+trametinib (I/II)

palbociclib (I/II)

binimetinib+BYL-719 (I)

BMS-906024 (I)

buparlisib+irinotecan (I)

cobimetinib+RG-7446 (I)

MEHD-7945A+cobimetinib (I)

PD-0325901+PF-04691502,PF-04691502+irinotecan,PD-0325901+

irinotecan

(I)

trametinib+uprosertib (I)

vorinostat+hydroxychloroquine (I)

*Mostadvancedphaseisshownandmultipleclinicaltrialsmaybeavailable.SeeOpenclinicaltrialssectioninthepagestofollow.

KRASA146mutationinColorectalCancer 1of9

Disclaimer:Thedatapresentedhereisaresultofthecurationofpublishedliterature,butmaynotbeexhaustive.

©2014ThermoFisherScientific.Allrightsreserved.

Oncomine CancerResearchPanelKnowledgebasev1.1®

PUBLISHED THERAPIES SUMMARY

Evidenceandprevalencesummarybyclass

Prevalence*

ClassEvidenceitems

Thiscancertype

KRASmutationstatus 2 35.5%

KRASmutation 15 35.5%

KRASnon-G12mutation 1 8.1%

KRASA146mutation 1 <1%

*Source:Oncomine CancerResearchPanelKnowledgebase(ThermoFisherScientific,AnnArbor,MI)

Publishedtherapiesdetail

cetuximab

cetuximab

Aclasshierarchywascreatedtosummarizegenevariantswithassociatedclinicalevidence.Evidenceitemsreferstouniquecitations

(CurrentFDAinformation,NCCNGuidelines,orclinicaltrialeligibilitycriteria).Anestimateofprevalenceofthegenevariantinthecancer

typeisprovided.

Inthiscancertype Inothercancertypes Inthiscancertypeandothercancertypes Contraindicated

NCCNGuidelines

NCCNGuidelinesinformationiscurrentasof2014-07-01.Forthemostup-to-dateinformation,gotowww.nccn.org.

Cancertype:ColorectalCancer

Class:

KRASmutation

Contraindication:

Baseduponlower-levelevidence,thereisuniformNCCNconsensus(Category2A)that

patientswithanyknownKRASorNRASmutationshouldnotbetreatedwitheither

cetuximaborpantitumumab.(COL-A4of5,MS-34)

Reference:

NCCNGuidelineVersion3.2014ColonCancer

Cancertype:ColorectalCancer

Class:

KRASmutation

Contraindication:

Baseduponlower-levelevidence,thereisuniformNCCNconsensus(Category2A)that

patientswithanyknownKRASorNRASmutationshouldnotbetreatedwitheither

cetuximaborpantitumumab.(REC-A5of6,MS-29andMS-30)

Reference:

NCCNGuidelineVersion3.2014RectalCancer


®




PUBLISHED THERAPIES DETAIL - NCCN GUIDELINES

Openclinicaltrials(cont'd)

Clinicaltrialinformationiscurrentasof2014-07-01.Forthemostup-to-dateinformationregardingaparticulartrial,search

www.clinicaltrials.govbyNCTID.

NCT01449058:APhaseIbOpen-label,

Multi-center,DoseEscalationand

ExpansionStudyofOrallyAdministered

MEK162PlusBYL719inAdultPatients

WithSelectedAdvancedSolidTumors

Class:

KRASmutation

Populationsegment(s):

HER2negative,Highrisk,Secondlineorgreater/Refractory/Relapsed,StageII,StageIII,

StageIV,Triplereceptornegative

Phase:

I

Publishedtherapy:

binimetinib+BYL-719

Location(s):

CA,IL,MA,TX,UT

Contact:

NovartisPharmaceuticals[1-862-778-8300]

NCT01304602:APhaseITrialof

IrinotecanandBKM120inPreviously

TreatedAdvancedColorectalCancer

Class:

KRASmutation

Populationsegment(s):

Secondlineorgreater/Refractory/Relapsed,StageIII,StageIV

Phase:

I

Publishedtherapy:

buparlisib+irinotecan

Location(s):

KS

Contact:

StaceyPurinton[913-588-2545;[email protected]]





PUBLISHED THERAPIES DETAIL - OPEN CLINICAL TRIALS

SUBJECT INFORMATION SITE INFORMATION

: ___________ ( )

Date of B irth: ___ ______ (dd/mm/yyyy)

Site ID: ____ ____ _______

Gender: M F Phone: ________________ :____ ______ ___________

SPECIMEN INFORMATION

No.: __ ________________ Date S pecimen R eceived: ______ __________ Date Reported: _______________

T

TEST RESULTS

In this cancer type In other cancer type In this cancer type and other cancer types

Contraindicated No evidence available

Mutations

Gene Amino Acid

Change Geneotype Class cation

Current FDA Information

NCCN Guideline

Number of therapies with clinical trials in this

therapies

2 15

1 1

3

KRAS p.Ala146Thr c.436G>A Gain of F unction

KIT p.Met541Leu c.1612A>C Gain of F unction

MET p.Asn375Ser c.1124A>G Gain of F unction

Copy Number Variations

Gene Type Class cation Current FDA Information

NCCN Guideline


ER

Other mutations, copy number variations, or fusions that were detected but not classi ed by the Oncofocus Knowledgebase as a genetic driver of cancer are not listed in the results section of this report. All other genes listed in the Test Description that do not appear in the results section either did not have a detected variant or the variant is not classi ed as a genetic driver for cancer.

Fusion n s

3 15 2

RET Fusion 1

Class cation Current FDA Information

NCCN Guideline


1

Oncologica UK Ltd, Suite 15-16, The Science Village, Chesterford Research Park, Cambridge, CB10 1XL

www.oncologica.com - Tel: +44 (0)1223 785327 - [email protected]

Oncofocus Patient Test Report

Read the Full Report onhttp://oncologica.com/report

14 15

PROFILING FLOW EXAMPLE

LONGITUDINAL DYNAMIC MONITORINGOF PATIENTS RECEIVING TARGETED THERAPIES

Candidate treatment:erlotinib,gefitinib,

afatinib,dacomitinibneratinib

Candidate treatment:AZD-9291

Routine histologicalsamples

Liquid biopsye.g.ctDNA, CTCs

Initial profiling e.g EGFR L858Rmutation

Primary diagnosis

Relapse

Secondary profiling,e.g. EGFR T790Mresistance mutation

21 4 5 6 73

SERVICE FLOW

TURNAROUND TIME:10 DAYS

Prepare template

Template enrichment

Run sequence

Data Analysis

Report generation Return of hardcopy and sample

Secure electronictransfer of report

DNA+RNA extraction

Construct Library

Sample receiptFFPE block, curlor liquid biopsy

ACTIONABLE DIAGNOSIS

DRUG RESPONSIVENESS ANALYSIS

CLINICAL TRIALS INFORMATION

ONCOFOCUS PATIENT TEST REPORT

Alteration Tumour type Example treatment(s)

ALK fusion NSCLC ceritinib, crizotinib

AKT1 mutation Multi cancer MK-2206, MSC-2363318A

*BAP1 mutation Melanoma vorinostat

BRAF mutation Melanoma dabrafenib, trametinib, vemurafenib

BRAF mutation NSCLC dabrafenib, vemurafenib

BRCA1 mutation, deletion Multi cancer rucaparib, veliparib

BRCA2 mutation, deletion Multi cancer rucaparib, veliparib

CCND1 amplification Multi cancer palbociclib

CDK4 amplification, mutation Melanoma, NSCLC palbociclib

CDK6 amplification NSCLC palbociclib

*CDKN2A mutation Multi cancer crizotinib + dasatinib, palbociclib

DDR2 mutation Multi cancer crizotinib + dasatinib

EGFR mutation NSCLC afatinib, erlotinib

ERBB2 amplification Breast cancer pertuzumab, trastuzumab

ERBB2 amplification Gastric cancer trastuzumab

ERBB2 amplification NSCLC afatinib

ERBB3 mutation Multi cancer neratinib

FGFR1-4 mutation, amplification, fusion

Multi cancer BGJ-398, JNJ-42756493

GNA11 mutation Melanoma vorinostat

GNAQ mutation Melanoma vorinostat

HRAS mutation Multi cancer binimetinib + panitumumab, BVD-523

Approved - FDA labels Investigational - TrialsApproved - NCCN

EXAMPLES OF GENETIC VARIANTSAND TARGETED TREATMENTS

*available soon

IDH1 mutation Multi cancer AG-120

KIT amplification Melanoma dasatinib

KIT mutation Melanoma imatinib mesylate

KIT mutation GIST imatinib, sunitinib, regorafenib

KRAS mutation Colorectal cancer cetuximab, panitumumab contraindicated

KRAS mutation Multi cancer various MEKi combinations

MET amplification NSCLC crizotinib

MET mutation Multi cancer AMG-337, crizotinib, INCB-028060

MTOR mutation Multi cancer MSC-23633188A

MYCN amplification Multi cancer GSK-525762

NRAS mutation Colorectal cancer cetuzimab, panitumumab contraindicated

NRAS mutation Multi cancer various MEKi combinations

PDGFRA amplification Glioblastoma nilotinib, sorafenib

PDGFRA mutation GIST dasatinib

PIK3CA mutation Multi cancer various PI3K pathway combinations

PPARG fusion Thyroid cancer pioglitazone

*PTCH1 mutation Multi cancer vismodegib

PTEN deletion, mutation Multi cancer various PI3K pathway combinations

RET fusion NSCLC cabozantinib

RET mutation NSCLC, Thyroid cancer ponatinib, sunitinib

ROS1 fusion NSCLC crizotinib

SMO mutation Multi cancer vismodegib

STK11 mutation Multi cancer MSC-2363318A

TP53 mutation Multi cancer MK-1775, MK-8242

*TSC1,2 m utation Multi cancer MSC-2363318A

Alteration Tumour type Example treatment(s)

18 19

Oncofocus was developed as part of the US NCI-MATCH (Molecular Analysis for Therapy Choice) program for precision oncology involving 2400 NCI-affiliated hospitals, >700,000 patients samples, 120 phase 3 and 215 early phase trials.

The Oncofocus test utilises state of the art semiconductor technology to rapidly sequence DNA/RNA extracted from routine FFPE surgical biopsy material. The assay is designed to detect thousands of genetic alterations including SNPs, indels, CNVs and fusions across 52 of the major cancer driver genes linked to solid tumours. The data generated by the Oncofocus test is analysed using Oncologica’s bionformatics platforms linked to the world’s largest curated compendium of cancer genetic information, enabling genetic alterations/variants to be linked to over 280 targeted therapies. Targeted therapies include all classes: -FDA approved therapies, -national comprehensive cancer network (NCCN) guideline referenced therapies and -therapies entered into US, EU and Japanese phase I, II and III clinical trials.

ONCOLOGICA TEST MENU FOR PERSONALISED ONCOLOGY

ONCOFOCUS PANEL52 GENE LIST SUMMARY

Additional tests for targeted therapies available.Please visit www.oncologica.com or contact us for more information

CNV HOTSPOT + CNV + FUSIONFUSION HOTSPOT HOTSPOT + FUSION CNV + FUSIONHOTSPOT + CNV

AKT1ALK AR BRAF CDK4CTNNB1 DDR2 EGFR ERBB2 ERBB3 ERBB4 ESR1 FGFR2

FGFR3 GNA11 GNAQ HRASIDH1IDH2JAK1JAK2JAK3 KITKRAS MAP2K1 MAP2K2

METMTOR NRASPDGFRA PIK3CA RAF1RETROS1SMO

HOTSPOTGENES

ALK AR BRAF CCND1 CDK4 CDK6 EGFR ERBB2 FGFR1 FGFR2 FGFR3 FGFR4 KIT

KRAS MET MYC MYCN PDGFRA PIK3CA

COPY NUMBER VARIANTS

35 19 23

ABL1AKT3ALKAXLBRAFEGFRERBB2ERGETV1ETV4ETV5FGFR1FGFR2

FGFR3METNTRK1NTRK2NTRK3PDGFRAPPARGRAF1RETROS1

FUSION DRIVERS

Oncofocus Test Comprehensive NGS targeted panel for precision therapy

52to

Genes relevantto solid tumors

gene alterations

aligneddetection of thousands of

variants

targeted therapies andmany more

undergoing clinical trials

over 270

20 21

Professor Gareth Williams and Dr Marco Loddo are Co-founders and Directors of Oncologica and have in-depth knowledge and expertise in diagnostic oncopathology, translational biology, biomarker discovery and drug development.

Kitty Williams is the Senior Commercial Manager and is responsible for providing advice and implementation on commercial and corporate matters

Philippa Jones is the Senior Operations Manager and directs the tissue based diagnostic services of the company.

Katherine Marquis is the Senior Biomedical Scientist who directs the precision oncology services for targeted therapies

Keeda-Marie Snelson is the Lead Clinical Scientist with extensive expertise in the analysis of cancer genetic variants of clinical prognostic and predictive significance.

Rebecca Cadman is the Business Development Manager and is responsible for exploring new market opportunities and providing comprehensive support for existing clients.

MANAGEMENT TEAM

Read more about our team by visitng www.oncologica.com/about-us/our-team/

Suite 15-16, The Science Village, Chesterford Research Park, Cambridge, CB10 1XL

www.oncologica.com

TELEPHONE

MAIL

+44 (0)1223 785327

[email protected]

22

Suite 15-16, The Science Village, Chesterford Research Park Cambridge, CB10 1XL

ww

w.dbs.agency

V150915193433U

K

www.oncologica.com

“The linking of specific cancer genetic alterations to molecular ...€¦ · “The linking of...

Documents

Transcript of “The linking of specific cancer genetic alterations to molecular ...€¦ · “The linking of...